Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4282794
Max Phase: Preclinical
Molecular Formula: C100H140N24O38S
Molecular Weight: 2318.42
Molecule Type: Unknown
Associated Items:
ID: ALA4282794
Max Phase: Preclinical
Molecular Formula: C100H140N24O38S
Molecular Weight: 2318.42
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CSCC[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)NC(=O)CCNC(=O)CCNC(=O)c1ccc(C(=O)O)c(C2c3ccc(O)cc3OC3=CC(=O)C=CC32)c1)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(N)=O
Standard InChI: InChI=1S/C100H140N24O38S/c1-44(2)27-59(83(104)143)114-94(154)64(35-74(103)130)119-98(158)69(41-125)124-97(157)68(39-81(141)142)120-88(148)58(22-26-163-8)111-84(144)47(7)109-89(149)66(37-79(137)138)121-90(150)60(28-45(3)4)116-92(152)62(31-49-40-105-43-108-49)117-96(156)67(38-80(139)140)122-99(159)70(42-126)123-91(151)61(29-46(5)6)115-87(147)57(18-19-77(133)134)113-93(153)63(34-73(102)129)118-86(146)56(11-9-10-23-101)112-95(155)65(36-78(135)136)110-76(132)21-24-106-75(131)20-25-107-85(145)48-12-15-52(100(160)161)55(30-48)82-53-16-13-50(127)32-71(53)162-72-33-51(128)14-17-54(72)82/h12-17,30,32-33,40,43-47,53,56-70,82,125-126,128H,9-11,18-29,31,34-39,41-42,101H2,1-8H3,(H2,102,129)(H2,103,130)(H2,104,143)(H,105,108)(H,106,131)(H,107,145)(H,109,149)(H,110,132)(H,111,144)(H,112,155)(H,113,153)(H,114,154)(H,115,147)(H,116,152)(H,117,156)(H,118,146)(H,119,158)(H,120,148)(H,121,150)(H,122,159)(H,123,151)(H,124,157)(H,133,134)(H,135,136)(H,137,138)(H,139,140)(H,141,142)(H,160,161)/t47-,53?,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,82?/m0/s1
Standard InChI Key: NRUDKWCWETWQQK-KURBARKFSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 2318.42 | Molecular Weight (Monoisotopic): 2316.9481 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Ran X, Burchfiel ET, Dong B, Rettko NJ, Dunyak BM, Shao H, Thiele DJ, Gestwicki JE.. (2018) Rational design and screening of peptide-based inhibitors of heat shock factor 1 (HSF1)., 26 (19): [PMID:29661622] [10.1016/j.bmc.2018.04.018] |
Source(1):